As BluMaiden Biosciences CEO and founder, Damien Keogh, PhD, leads an AI-driven platform identifying biomarkers and small molecule therapeutics from the human microbiome. With a decade’s biotech experience, he’s pioneered, pitched, funded scalable solutions for clinical gaps, and markets.

Dr. Keogh has a strong background in microbiome research and therapeutics, co-authoring several publications, patents, and awards in the field of microbiome, glycobiology, and gene regulation. He established strategic global partnerships with clinical institutions, biotech, pharma, and venture firms. Dr. Keogh is passionate about advancing the science and business of microbiome-based medicine and empowering his team to deliver impactful, transformative outcomes.